Pages that link to "Q40453891"
Jump to navigation
Jump to search
The following pages link to Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. (Q40453891):
Displaying 50 items.
- αV integrins in angiogenesis and cancer (Q26851768) (← links)
- Integrins in cancer: biological implications and therapeutic opportunities (Q29614536) (← links)
- Preclinical molecular imaging of tumor angiogenesis. (Q30475818) (← links)
- Hypoxia, inflammation, and the tumor microenvironment in metastatic disease (Q33576030) (← links)
- Integrins as "functional hubs" in the regulation of pathological angiogenesis (Q33591910) (← links)
- Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix. (Q33620142) (← links)
- Significance of Talin in Cancer Progression and Metastasis (Q33763551) (← links)
- Fibroblast heterogeneity in the cancer wound (Q33964324) (← links)
- Integrin alpha(v)beta(3)-Targeted Cancer Therapy (Q33983773) (← links)
- Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs (Q34011214) (← links)
- Application of quantitative pharmacology in development of therapeutic monoclonal antibodies (Q34293689) (← links)
- Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models (Q34480549) (← links)
- Why integrin as a primary target for imaging and therapy (Q34912582) (← links)
- Integrin Targeted Therapeutics (Q34912684) (← links)
- Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. (Q35093966) (← links)
- A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma (Q35212620) (← links)
- Integrin inhibitors as a therapeutic agent for ovarian cancer (Q35660004) (← links)
- aV integrins and TGF-β-induced EMT: a circle of regulation (Q35791382) (← links)
- Characterizing at-Risk Voxels by Using Perfusion Magnetic Resonance Imaging for Cervical Cancer during Radiotherapy (Q36800482) (← links)
- Expression of αV-Integrins in Uterine Serous Papillary Carcinomas; Implications for Targeted Therapy With Intetumumab (CNTO 95), a Fully Human Antagonist Anti-αV-Integrin Antibody (Q36949302) (← links)
- The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma (Q37006613) (← links)
- Integrins and metastasis (Q37014793) (← links)
- Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model (Q37053185) (← links)
- Clinical biomarkers of angiogenesis inhibition (Q37139413) (← links)
- Integrins in angiogenesis and lymphangiogenesis (Q37170752) (← links)
- Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody (Q37230907) (← links)
- Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives (Q37232368) (← links)
- Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth (Q37328406) (← links)
- Roles of integrins in tumor angiogenesis and lymphangiogenesis. (Q37354204) (← links)
- Focal adhesion complex proteins in epidermis and squamous cell carcinoma. (Q37452962) (← links)
- Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013 (Q37496388) (← links)
- Environment-mediated drug resistance: a major contributor to minimal residual disease (Q37582773) (← links)
- The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. (Q37604903) (← links)
- Interspecies scaling of therapeutic monoclonal antibodies: initial look (Q37616947) (← links)
- Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies (Q37628695) (← links)
- Integrin targeted drug and gene delivery (Q37679945) (← links)
- Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern? (Q37723147) (← links)
- Targeting integrins in hepatocellular carcinoma (Q37844564) (← links)
- Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets (Q37866123) (← links)
- Angiogenesis in cancer. Basic mechanisms and therapeutic advances (Q37916313) (← links)
- Targeting the tumor microenvironment by immunotherapy: part 2. (Q37952796) (← links)
- Tumor response assessments with diffusion and perfusion MRI. (Q37995577) (← links)
- A novel treatment for glioblastoma: integrin inhibition (Q37997092) (← links)
- A multi-targeted approach to treating bone metastases. (Q38175846) (← links)
- Effects of integrins and integrin αvβ3 inhibitor on angiogenesis in cerebral ischemic stroke (Q38221073) (← links)
- Metastasis review: from bench to bedside (Q38237985) (← links)
- Angiogenesis in cancer: Anti-VEGF escape mechanisms (Q38389975) (← links)
- Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins (Q38831148) (← links)
- Metastatic signature in lung cancer is associated with sensitivity to anti-integrin α(V) monoclonal antibody intetumumab (Q39027918) (← links)
- Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer (Q39218794) (← links)